ECEthem Turgay Cerit

Ethem Turgay Cerit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ethem Turgay Cerit has a total of 267 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Publisher Correction: Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus

    by Maxim S Petrov, Hajime Yamazaki, Guotao Lu, Ahmad H Al-Mrabeh, Claudio Luchini, Xiaowu Dong, Tsuyoshi Hamada, Yutong Liu, Hiroki Oyama, Susanne Rospleszcz, et al.

  • HMW adiponectin levels in mild autonomous cortisol secretion and non-functioning adrenal adenoma: Impact of cortisol autonomy

    by Tugba Barlas, Meric Coskun, Sabri Engin Altintop, Mehmet Muhittin Yalcin, Ethem Turgay Cerit, Alev Eroglu Altinova, Mujde Akturk, Ayhan Karakoc, Fusun Balos Toruner

  • Open Access

    Sleep quality and associated factors of hypothyroid patients: a cross-sectional study

    by Emine Özer Küçük, Zuhal Candan Yamak, Ethem Turgay Cerit, Hülya Nur Sodan, Gizem Özcan Akbay

    Aims: To evaluate sleep quality and identify sociodemographic and clinical factors associated with sleep quality among patients diagnosed with hypothyroidism.Methods: A descriptive cross-sectional approach was used, with data collected from February 5 through April 6, 2024, at a university hospital’s thyroid outpatient unit. The study enrolled 94 patients with confirmed hypothyroidism. Data were collected using a researcher-designed Patient Identification Form and the Pittsburgh Sleep Quality Index. Statistical evaluation included descriptive analyses, independent-samples t-tests, one-way ANOVA, and multiple linear regression.Results: Participants had a mean age of 51.72±11.18 years, with females comprising 89.4% of the sample. The mean sleep quality score was 7.21±4.77, and 62.8% of participants demonstrated poor sleep quality. Individuals with advanced educational backgrounds exhibited superior sleep quality, whereas those with concurrent health conditions and prior sleep difficulties showed substantially diminished sleep quality. Together, these three variables explained 22.0% of the variance in sleep quality outcomes (R²=0,22; F=8,31; p

  • Open Access

    The Evaluation of the Predictive Value of Early Postoperative Biochemical Parameters for Remission in Patients with Acromegaly

    by Afruz Babayeva, Meriç Coşkun, Öykü Öztürk, Selen Yılmaz, Fidan Yusifova, Ethem Turgay Cerit, Mehmet Muhittin Yalçın, Alev Eroğlu Altınova, Füsun Toruner, Mehmet Ayhan Karakoç, et al.

    Objective: This study aimed to evaluate the predictive value of growth hormone (GH), insulin-like growth factor-1 (IGF-1), calcium (Ca), and phosphorus (P) levels in the first 2-4 days after surgery for achieving biochemical remission in patients with newly diagnosed acromegaly. Methods: This retrospective cohort study included patients with acromegaly who underwent surgery. Preoperative and early postoperative days 2-4 (POD2-4), 3rd month, and 12th month serum levels of GH, IGF-1, Ca, and P were obtained. Age-normalized IGF-1 levels defined remission at 3-6 months, and patients were grouped accordingly. Results: Biochemical remission was achieved in 44 of 68 patients (64.7%). Preoperative GH, IGF-1, and Ca were significantly higher in the non-remission group (all P < .05), while P did not differ. In POD2-4, all parameters, including P, were significantly higher in the non-remission group (P < .05). Receiver operating characteristic (ROC) analysis showed that a GH ≤1.28 in POD2-4 (AUC = 0.858, sensitivity: 0.74, specificity: 0.88) and a ≥45.29% decrease in IGF-1 from preoperative values (AUC = 0.816; sensitivity: 0.73, specificity: 0.79) predicted remission. At 12 months, GH and IGF-1 remained significantly different, whereas Ca and P did not (P = .67 and P = .20). Conclusion: In patients with acromegaly, GH, IGF-1, Ca, and P levels measured in the first 2-4 days after surgery were found to be significantly lower in the remission group than in those who did not achieve remission. Postoperative GH levels and the percentage decrease in IGF-1 levels were associated with remission and may help with early risk stratification. Cite this article as: Babayeva A, Coskun M, Ozturk O, et al. The evaluation of the predictive value of early postoperative biochemical parameters for remission in patients with acromegaly. Endocrinol Res Pract. Published online September 1, 2026. doi: 10.5152/erp.2026.26985

  • Top Cited Papers

    Conceptual framework and expert guidance on intrapancreatic fat deposition: the Melbourne consensus

    by Maxim S Petrov, Hajime Yamazaki, Guotao Lu, Ahmad H Al-Mrabeh, Claudio Luchini, Xiaowu Dong, Tsuyoshi Hamada, Yutong Liu, Hiroki Oyama, Susanne Rospleszcz, et al.

    Intrapancreatic fat deposition (IPFD) has garnered appreciable attention across diverse medical disciplines amid the rising global burden of pancreatitis, pancreatic cancer and type 2 diabetes mellitus. Despite growing interest in the field, there remains no conceptual framework for it. To address this gap, 25 experts from 6 continents were brought together to develop guidance. Drawing on multiple peer-reviewed systematic reviews and applying an iterative, anonymous Delphi process, a consensus document was developed and ratified in Melbourne, Australia. The final document contains 58 recommendations - 30 reached unanimous agreement and 28 attained 90-99% agreement. The consensus formally defines fatty pancreas disorder (FPD) as a distinct pathological state, characterized by excessive IPFD that poses a risk to health. Assessment of IPFD is best performed with MRI. Expert-established diagnostic criteria enable identification and classification of FPD. Recognition of type 1 FPD (in individuals without excess body fat mass) and type 2 FPD (in individuals with excess body fat mass) is instrumental in gaining novel insights and tailoring preventive strategies to the individual. The Melbourne consensus is foundational in operationalizing the dissemination of new knowledge in the field, fostering intercontinental collaborations and, ultimately, addressing the global burden of diseases of the pancreas.


  • Open Access

    Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study

    by Sema Hepşen, Cem Haymana, Gizem Ertepe Küçükgöde, Büşra Özcan, Burak Özbaş, Arzu Or Koca, Berna İmge Aydoğan, Çiğdem Tura Bahadır, Emre Durcan, Volkan Yumuk, et al.

    Background: Real-world data directly comparing the safety, tolerability, and effectiveness of semaglutide and tirzepatide in patients with obesity remain limited. This nationwide multicenter observational study compared short-term adverse events, treatment discontinuation, body weight loss (BWL), and metabolic outcomes between the two treatments. Methods: This study included 2,549 patients with obesity treated with semaglutide (n=1,434) or tirzepatide (n=1,115). Adverse events, including time to onset, dose at occurrence, and related discontinuation, were evaluated. Changes in BWL and metabolic parameters up to 6 months were assessed. Subgroup analyses were performed in patients with and without type 2 diabetes mellitus (T2DM). Results: At least one adverse event occurred in 50.9% in the semaglutide group and 51.0% in the tirzepatide group (p=0.524), with gastrointestinal events the most frequently reported. Overall adverse event rates were comparable between groups; however, musculoskeletal and allergic reactions were more common in the tirzepatide group. The onset of gastrointestinal, neuropsychiatric, musculoskeletal symptoms, and hypoglycemia occurred earlier in the tirzepatide group. Discontinuation due to adverse events was similar between groups, except for pancreatic events, which were more frequent in the semaglutide group (p=0.006). Tirzepatide was associated with greater early BWL at all time points. At 6 months, median percentage BWL was 12.6% with semaglutide and 14.4% with tirzepatide. HbA1c reductions were comparable between groups in patients with T2DM. Conclusion: In real-world clinical practice, semaglutide and tirzepatide show similar short-term tolerability and treatment persistence, although tirzepatide is associated with a higher incidence of musculoskeletal and allergic reactions and greater early BWL.


  • Open Access

    Altered Tryptophan–Kynurenine Pathway and Low-Grade Inflammation in Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD): Insights from LC–MS/MS–Based Metabolite Profiling

    by Kübranur Ünal, Leyla İbRahimkhanlı, Mehmet Emre Erol, Nemat İbRahimkhanlı, Sabri Engin Altıntop, Mahi Nur Cerit, Ethem Turgay Cerit, Halit Nahit Şendur

    Metabolic dysfunction–associated steatotic liver disease (MASLD) is a multisystem disorder characterized by hepatic lipid accumulation, low-grade inflammation, and metabolic dysregulation. Although the kynurenine pathway has been implicated in the pathogenesis of metabolic and inflammatory diseases, its contribution to MASLD remains unclear. This study aimed to evaluate tryptophan (TRP) metabolism and its relationship with inflammatory biomarkers and lipid parameters across different grades of steatosis. A total of 88 adults (62 MASLD, 26 healthy controls; aged 20-69 years) were enrolled in this study. Serum concentrations of inflammatory markers (CRP, IL-6, and TNF-α) were determined using immunoassay-based methods, and TRP metabolites (TRP, KYN, KYNA, 3-HK, 3-HAA, QA, PIC) were quantified using validated LC–MS/MS. Steatosis grades (0-3) were assessed via ultrasonography. Statistical analyses included the Mann–Whitney U test, the Kruskal–Wallis test, and the Spearman correlation test. MASLD subjects showed significantly higher BMI, triglycerides, AST, ALT, GGT, CRP, TNF-α, and KYNA levels compared with controls (all P < .05), while HDL-C levels were lower ( P = .014). Across steatosis grades, BMI, TG, and CRP increased progressively ( P < .001), and IL-6 showed a positive correlation with steatosis severity ( r = .280, P < .05). KYNA levels were elevated in early steatosis (Grade 1, P = .008) and inversely correlated with TC and LDL-C ( r = −.393 and r = −.384, respectively). The elevation of KYNA may reflect an early compensatory mechanism imitigating hepatic and metabolic stress. Integrating inflammatory and kynurenine pathway biomarkers could improve disease stratification and therapeutic targeting in MASLD.


  • Open Access

    Serum biomarkers and non-invasive indices for discriminating MASLD among adults with dysglycaemia

    by Kübranur Ünal, Leyla İbRahimkhanlı, Mehmet Emre Erol, Sabri Engin Altıntop, Nemat İbRahimkhanlı, Halit Nahit Şendur, Mahi Nur Cerit, Ethem Turgay Cerit

    Objectives: Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide. Although dysglycaemia is a major risk factor, additional cardiometabolic disturbances contribute to the development of MASLD. This study aimed to identify parameters that distinguish MASLD among dysglycaemic individuals using body composition, anthropometric, biochemical, and imaging-based assessments. Methods: In this cross-sectional study, male and female adults were stratified into three groups: dysglycaemic individuals with MASLD (MASLD-Dys), dysglycaemic individuals without MASLD (Dys), and normoglycaemic individuals without MASLD as healthy controls. Imaging-based hepatic fat quantification, body composition, anthropometric and biochemical parameters, and non-invasive indices assessing hepatic steatosis and fibrosis were evaluated. Results: Compared with Dys participants, MASLD-Dys participants had higher body mass index (BMI), waist circumference, trunk fat mass, ultrasound-derived hepatic fat fraction (USFF), and Fatty Liver Index (FLI). The strongest between-group separation was observed for USFF (p<0.001). In receiver operating characteristic analysis, USFF showed the highest discriminative performance for MASLD-Dys vs. Dys, with an area under the curve of 0.925 and an optimal cut-off of ≥6.95 %. Conclusions: USFF was the strongest discriminator of MASLD among dysglycaemic adults, while FLI provided a practical non-imaging alternative. These findings support integrating hepatic fat quantification and body composition measures into MASLD risk stratification beyond glycaemic status alone.

  • Open Access

    Endocrine disruptors, obesity, and metabolic syndrome

    by Tuğba Barlas, Alev Eroğlu Altinova, Meriç Coşkun, Ethem Turgay Ceri̇t

    The global prevalence of obesity and metabolic syndrome (MetS) is rising worldwide, and increasing evidence suggests that chemical exposures—particularly endocrine disruptors (EDs)—represent a significant contributing factor. EDs can act as obesogens, increasing the risk of weight gain and related metabolic conditions, including type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. They may also alter the basal metabolic rate, gut microbiota composition, and hormonal regulation of appetite and satiety. EDs are reported to exert their effects mainly through the peroxisome proliferator-activated receptor gamma pathway, which is primarily expressed in adipose tissue and is a key regulator of adipogenesis. Common consumer products such as plastic bottles, metal food cans, detergents, toys, cosmetics, and pesticides frequently contain EDs. Humans can be exposed to these chemicals via multiple routes, including transplacental transfer, breast milk, inhalation, ingestion, and dermal absorption. Bisphenols, tributyltin, phthalates, per- and polyfluoroalkyl substances, polycyclic aromatic hydrocarbons, and heavy metals are among the known EDs that have been associated with obesity and MetS. The need for further investigation and stricter regulations to mitigate the public health consequences of environmental exposure to EDs is consistently emphasized in recent literature. Understanding the mechanisms by which EDs affect various hormones and systems is essential for developing effective prevention and intervention strategies. In this review, we discuss the relationship between obesity, MetS, and EDs, along with exposure pathways and preventive strategies.


  • Open Access

    Endocrine disruptors, insulin resistance, and diabetes

    by Meri̇ç Coşkun, Ethem Turgay Ceri̇t, Tuğba Barlas, Alev Eroğlu Altinova

    Endocrine-disrupting chemicals (EDCs) are compounds that interfere with hormone synthesis, secretion, metabolism, or excretion. Evidence indicates that increased exposure to EDCs is associated with insulin resistance and, most notably, type 2 diabetes worldwide. This suggests a diabetogenic effect that is independent of obesity, underscoring the complex mechanisms and broad impact of EDCs on metabolic health. Key pathways include hormone mimicry and antagonism, altered hormone metabolism, inflammatory responses, and mitochondrial dysfunction. This review summarises the mechanisms through which EDCs contribute to these conditions and evaluates the epidemiological and experimental evidence supporting these associations.